Table 3.

Summary of the analyzed studies regarding tocilizumab

Study	Design	Patients	Eyes	Previous treatment of DON with ivMP /OD/ORT	Simultaneous treatment	Tocilizumab infusionsa	Resolution of DONc-% of all eyes	FU in weeks	Recurrence of DON during FU	OD after Tocilizumab during FU
Mehmet et al. [72]	Case report	1	2	ivMP, ORT	–	4	100%	12	No	No
Kaplan et al. [76]	Case report	1	1	ivMP, OD, ORT	–	11	100%	84	Yese	No
Pascual-Camps et al. [71]	Case report	1	2	–	–	4	100%	64	No	No
Maldiney et al. [75]	Case report	1	1	ivMP	ivMP	8	100%	28	No	No
Rodríguez et al. [74]	Case report	1	1	ivMP, OD	–	6	100%	16	No	No
Sy et al. [73]	Case series	2	2	ivMP, OD	–	4/4b	100%	12	No	No
Sánchez-Bilbao et al. [70]	Case series	7	7	ivMP, OD	Missing	Missing	Improvement in VA insignificant	65d	Missing	Missing

DON dysthyroid optic neuropathy, ivMP intravenous methylprednisolone, OD orbital decompression, ORT orbital radiotherapy, FU follow-up, VA visual acuity, RAPD relative afferent pupillary defect

^aNumber of infusions (8 mg/kg every 4 weeks, intravenously)

^bNumber of infusions each patient received

^cDefined as stabilization of disease with no need of further DON treatment and improvement in VA and/or color vision/visual field/RAPD

^dMean time

^eRecurrence of DON after 10 months following the first six infusions of tocilizumab; patient received five additional infusions obtaining again resolution of DON